Cellogen Therapeutics
Cellogen Therapeutics is dedicated to developing innovative cellular engineering and gene therapy-based treatments for cancers and blood disorders. Their focus is on creating next-generation CAR T-cell therapies and gene manipulation techniques to provide affordable, effective, and long-lasting cures, especially targeting hematological malignancies, solid tumors, and hemoglobinopathies. They collaborate with leading research institutes and have received significant investments to support their mission of making advanced therapies accessible to the masses, particularly in India.
Industries
Nr. of Employees
small (1-50)
Cellogen Therapeutics
Noida, Uttar Pradesh, India
Products
Preclinical bispecific CAR T-cell therapy candidates
Candidate CAR-T constructs engineered to target multiple antigens simultaneously with optimized co-stimulatory domains and demonstrated superior in vitro and in vivo anti-tumor activity in preclinical models.
Gene-manipulation therapeutic candidates for hemoglobinopathies
Preclinical gene-editing approaches (CRISPR and vector-based) designed to recreate beneficial HPFH genotypes or add functional globin gene copies to correct sickle cell disease and beta-thalassemia phenotypes.
Custom Lentiviral Vector Manufacturing
High-titer, high-purity lentiviral vector production platform designed for research-grade and translational science applications, supporting genetic engineering and CAR-T development.
LV DO Lentivirus Concentrator
An innovative solution designed to concentrate lentiviral vectors, integrated with an AI-based Chatbot Assistant for titer calculations, reagent ratios, troubleshooting tips, and protocol clarifications.
Gene-editing and Cellular Therapies for Hemoglobinopathies
Genetic therapies utilizing CRISPR and stem cell transplantation to address blood disorders like beta-thalassemia and sickle cell disease.
3rd and 4th generation CAR T-cell therapies
Cutting-edge bi-specific, 3rd and 4th generation CAR T-cell therapies engineered for enhanced precision and potency, targeting leukemia and lymphoma.
Preclinical bispecific CAR T-cell therapy candidates
Candidate CAR-T constructs engineered to target multiple antigens simultaneously with optimized co-stimulatory domains and demonstrated superior in vitro and in vivo anti-tumor activity in preclinical models.
Gene-manipulation therapeutic candidates for hemoglobinopathies
Preclinical gene-editing approaches (CRISPR and vector-based) designed to recreate beneficial HPFH genotypes or add functional globin gene copies to correct sickle cell disease and beta-thalassemia phenotypes.
Custom Lentiviral Vector Manufacturing
High-titer, high-purity lentiviral vector production platform designed for research-grade and translational science applications, supporting genetic engineering and CAR-T development.
LV DO Lentivirus Concentrator
An innovative solution designed to concentrate lentiviral vectors, integrated with an AI-based Chatbot Assistant for titer calculations, reagent ratios, troubleshooting tips, and protocol clarifications.
Gene-editing and Cellular Therapies for Hemoglobinopathies
Genetic therapies utilizing CRISPR and stem cell transplantation to address blood disorders like beta-thalassemia and sickle cell disease.
3rd and 4th generation CAR T-cell therapies
Cutting-edge bi-specific, 3rd and 4th generation CAR T-cell therapies engineered for enhanced precision and potency, targeting leukemia and lymphoma.
Services
Design, in‑vitro functional testing and in‑vivo efficacy/safety evaluation of bi- and tri-specific CAR constructs and optimized co-stimulatory configurations to address antigen escape and persistence.
CRISPR-based and vector-mediated approaches to reactivate fetal hemoglobin or add functional HBB copies in patient-derived HSPCs, with preclinical engraftment and functionality assessment.
In silico support including AI-guided receptor design, high-throughput construct prioritization, virtual screening, molecular docking and QSAR to accelerate candidate selection.
Support for readiness activities and initiation of Phase I/II studies through clinical collaborations and regulatory engagement with national authorities.
Design, in‑vitro functional testing and in‑vivo efficacy/safety evaluation of bi- and tri-specific CAR constructs and optimized co-stimulatory configurations to address antigen escape and persistence.
CRISPR-based and vector-mediated approaches to reactivate fetal hemoglobin or add functional HBB copies in patient-derived HSPCs, with preclinical engraftment and functionality assessment.
In silico support including AI-guided receptor design, high-throughput construct prioritization, virtual screening, molecular docking and QSAR to accelerate candidate selection.
Support for readiness activities and initiation of Phase I/II studies through clinical collaborations and regulatory engagement with national authorities.
Expertise Areas
- CAR T-cell therapy development
- Gene editing for hemoglobinopathies
- Preclinical translational research (in vitro and in vivo)
- AI-guided biomolecular design
Key Technologies
- CRISPR-Cas gene editing
- Lentiviral vector gene addition
- Bispecific and trispecific CAR platforms
- Targeted protein degradation strategies (PROTAC-like)
News & Updates
Natco Pharma invested $2 million in Cellogen Therapeutics to support the development of CAR T-cell therapies and gene manipulation technologies.
Natco Pharma invested $2 million in Cellogen Therapeutics to support the development of CAR T-cell therapies and gene manipulation technologies.